April 29, 2020 07:17 AM EDT
Deals
Cell/Gene Tx

Hav­ing sold its cor­po­rate self, Toca­gen auc­tions off sci­en­tif­ic plat­form to San Diego biotech

Jason Mast

Editor

With the der­mati­tis spe­cial­ists at Forte Bio­sciences now in­hab­it­ing Toca­gen’s cor­po­rate skele­ton, a small San Diego biotech has won rights to its sci­en­tif­ic plat­form …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times